Latest news with #Oxford®CementlessPartialKnee
Yahoo
05-05-2025
- Business
- Yahoo
Zimmer Biomet Announces First Quarter 2025 Financial Results
First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basis First quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81 Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposals WARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025. The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% over the prior year period, and an increase of 2.3% on a constant currency1 basis. Net earnings for the first quarter were $182.0 million, or $361.1 million on an adjusted1 basis. Diluted earnings per share were $0.91 for the first quarter, and adjusted1 diluted earnings per share were $1.81.1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release. "We are proud of our team's continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda," said Ivan Tornos, Zimmer Biomet's President and Chief Executive Officer. "We're excited about the momentum in U.S. Hips, fueled by our revamped portfolio inclusive of the Z1™ Triple-Taper Femoral Hip System, HAMMR® Automated Hip Surgical Impactor System, as well as navigation capabilities, and believe the early enthusiasm from surgeons for our new Oxford® Cementless Partial Knee positions us well to accelerate growth in the second half of the year. The recently completed acquisition of Paragon 28 is another bold step toward our innovation and diversification ambitions, expanding our S.E.T. business with leading technologies and a dedicated commercial channel in the high-growth foot and ankle segment." Recent Highlights Completed the acquisition of Paragon 28, Inc., a leading medical device company focused exclusively on the foot and ankle orthopedic segment, further strengthening Zimmer Biomet's position in this high-growth space. Showcased a broad portfolio of innovations at the 2025 American Academy of Orthopaedic Surgeons (AAOS) annual meeting, including a comprehensive hip portfolio anchored by the new Z1™ Triple-Taper Femoral Hip System, along with the latest technologies for knee and upper extremity reconstruction and key robotic solutions. In addition, Zimmer Biomet debuted ZBX™, its new Ambulatory Surgery Center (ASC) offering to surgeons and institutions looking to expand their orthopedic footprint. Received U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with sensitivities to certain metals. The product will be commercially available in the U.S. in Q3 2025. Launched the You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger, providing millions of people living with joint pain with an online community that empowers them with resources to make informed choices about their mobility. Announced upcoming changes to Zimmer Biomet's Board of Directors, effective at the Company's annual meeting of stockholders on May 29, 2025, including the retirement of Non-Executive Chairman Christopher Begley; the appointment of President and CEO Ivan Tornos as Chairman of the Board upon Mr. Begley's retirement; and the naming of Michael Farrell as Lead Independent Director upon Mr. Begley's retirement. Appointed Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer, and Kristen Cardillo as Senior Vice President, Chief Communications Officer, to the Zimmer Biomet Executive Leadership Team. Named one of the 2025 World's Most Ethical Companies® by Ethisphere. Geographic and Product Category Sales The following sales table provides results by geography and product category for the three-month period ended March 31, 2025, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis. NET SALES - THREE MONTHS ENDED MARCH 31, 2025 (in millions, unaudited) ConstantNet CurrencySales % Change% Change Geographic Results United States $ 1,113.61.3% 1.3% International795.50.7 3.7 Total $ 1,909.11.1% 2.3% Product Categories Knees United States $ 459.00.2% 0.2% International333.91.2 4.2 Total792.90.6 1.9 Hips United States264.33.7 3.7 International231.5(2.0) 1.0 Total495.80.9 2.4 S.E.T. *470.53.9 4.9 Technology & Data, Bone Cement and Surgical **149.9(4.7) (3.5) Total $ 1,909.11.1% 2.3%* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic ** Historically referred to as "Other" Amounts reported in millions are computed based on the actual amounts. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Percentages presented are calculated from the underlying unrounded amounts. Financial Guidance The Company is updating its full-year 2025 reported revenue guidance to include the Paragon 28, Inc. ("Paragon 28") acquisition and currency expectations, and full-year 2025 adjusted earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposals: Projected Year Ending December 31, 2025 Previous Guidance Updated Guidance 2025 Reported Revenue Change 1.0% - 3.5% 5.7% - 8.2% Foreign Currency Exchange Impact (2.0)% - (1.5)% 0.0% - 0.5% 2025 Constant Currency Revenue Change N/A 5.7% - 7.7% 2025 Organic Constant Currency Revenue Change(1) 3.0% - 5.0% 3.0% - 5.0% Adjusted Diluted EPS(2) $8.15 - $8.35 $7.90 - $8.10(1) Excludes the projected impact of the Paragon 28 acquisition. Reconciliation of this measure to the most directly comparable GAAP financial measure is included in this press release. (2) These measures are non-GAAP financial measures for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See "Forward-Looking Non-GAAP Financial Measures" below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. Conference Call The Company will conduct its first quarter investor conference call today, May 5, 2025, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at It will be archived for replay following the conference call. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit or follow on LinkedIn at or X / Twitter at Website Information We routinely post important information for investors on our website, in the "Investor Relations" section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website or any other website referenced herein is not incorporated by reference into, and is not a part of, this document. Note on Non-GAAP Financial Measures This press release and our commentary in our investor conference call today include non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP. Net sales change information for the three-month period ended March 31, 2025 is presented on a GAAP (reported) basis and on a constant currency basis. Projected net sales change information for the year ended December 31, 2025, is also presented on an organic constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases. In addition to excluding the projected effects of foreign currency exchange rates, projected 2025 organic constant currency revenue change also excludes the projected impact on net sales from the April 2025 acquisition of Paragon 28. Net earnings and diluted earnings per share for the three-month periods ended March 31, 2025 and 2024 are presented on a GAAP (reported) basis and on an adjusted basis. These adjusted financial measures exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in the press release. Free cash flow is an additional non-GAAP measure that is presented in this press release. Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash provided by operating activities. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release. This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company presents in other contexts. These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation. Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures. In addition, constant currency revenue, adjusted operating profit, adjusted diluted earnings per share and free cash flow are used as performance metrics in our incentive compensation programs. Forward-Looking Non-GAAP Financial Measures This press release and our commentary in our investor conference call today also include certain forward-looking non-GAAP financial measures for the year ending December 31, 2025. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, we exclude the impact of certain charges related to initial compliance with the European Union Medical Device Regulation; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; and certain legal and tax matters. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding financial guidance, statements regarding macro pressures, including the impact of such pressures on our business, and any statements about our forecasts, expectations, plans, intentions, strategies or prospects. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: competition; pricing pressures; dependence on new product development, technological advances and innovation; changes in customer demand for our products and services caused by demographic changes, obsolescence, development of different therapies or other factors; our ability to attract, retain, develop and maintain adequate succession plans for the highly skilled employees, senior management, independent agents and distributors we need to support our business; shifts in the product category or regional sales mix of our products and services; the risks and uncertainties related to our ability to successfully execute our restructuring plans; control of costs and expenses; risks related to the ability to realize the anticipated benefits of the acquisition of Paragon 28, including the possibility that the expected benefits from the transaction will not be realized or will not be realized within the expected time period; the risk that the businesses of Paragon 28 will not be integrated successfully; disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including with customers, vendors, service providers, independent sales representatives, agents or agencies; the effects of business disruptions affecting us, our suppliers, customers or payors, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; unplanned delays, disruptions and expenses attributable to our enterprise resource planning and other system updates; the ability to form and implement alliances; dependence on a limited number of suppliers for key raw materials and other inputs and for outsourced activities; the risk of disruptions in the supply of materials and components used in manufacturing or sterilizing our products; breaches or failures of our (or of our business partners' or other third parties') information technology systems or products, including by cyberattack, unauthorized access or theft; the outcome of government investigations; the impact of healthcare reform and cost containment measures, including efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, through reductions in reimbursement levels, repayment demands and otherwise; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; changes in tax obligations arising from examinations by tax authorities and from changes in tax laws in jurisdictions where we do business, including as a result of the "base erosion and profit shifting" project undertaken by the Organisation for Economic Co-operation and Development and otherwise; challenges to the tax-free nature of the ZimVie Inc. spinoff transaction and the subsequent liquidation of our retained interest in ZimVie Inc.; the risk of additional tax liability due to the recategorization of our independent agents and distributors to employees; changes in tariffs relating to imports to the U.S. and other countries; the risk that material impairment of the carrying value of our intangible assets, including goodwill, could negatively affect our operating results; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; changes in general industry and market conditions, including domestic and international growth, inflation and currency exchange rates; the domestic and international business impact of political, social and economic instability, tariffs, trade restrictions and embargoes, sanctions, wars, disputes and other conflicts, including on our ability to operate in, export from or collect accounts receivable in affected countries; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration ("FDA") and other government regulators relating to medical products, healthcare fraud and abuse laws and data privacy and cybersecurity laws; the success of our quality and operational excellence initiatives; the ability to remediate matters identified in inspectional observations issued by the FDA and other regulators, while continuing to satisfy the demand for our products; product liability, intellectual property and commercial litigation losses; and the ability to obtain and maintain adequate intellectual property protection. A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and our subsequent filings with the Securities and Exchange Commission (SEC). Copies of these filings are available online at or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release. Note: Amounts reported in millions within this press release are computed based on the actual amounts. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts. ZIMMER BIOMET HOLDINGS, CONSOLIDATED STATEMENTS OF EARNINGSFOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024(in millions, except per share amounts, unaudited) 2025 2024Net Sales $ 1,909.1 $ 1,889.2Cost of products sold, excluding intangible asset amortization549.8512.3Intangible asset amortization151.0142.1Research and development110.6107.9Selling, general and administrative758.8736.2Restructuring and other cost reduction initiatives36.0124.4Acquisition, integration, divestiture and related10.60.4Operating expenses1,616.81,623.3Operating Profit292.3265.9Other income (expense), net2.9(0.1)Interest expense, net(66.2)(50.7)Earnings before income taxes229.0215.1Provision for income taxes46.542.3Net Earnings182.6172.8Less: Net earnings attributable to noncontrolling interest0.60.4Net Earnings of Zimmer Biomet Holdings, Inc. $ 182.0 $ 172.4Earnings Per Common ShareBasic $ 0.92 $ 0.84Diluted $ 0.91 $ 0.84Weighted Average Common Shares OutstandingBasic198.9205.2Diluted199.7206.2 ZIMMER BIOMET HOLDINGS, CONSOLIDATED BALANCE SHEETS(in millions, unaudited)March 31, December 31,2025 2024Assets Cash and cash equivalents$ 1,384.5 $ 525.5Receivables, net 1,533.41,480.7Inventories 2,244.22,235.3Other current assets 428.2430.1Total current assets 5,590.24,671.5Property, plant and equipment, net 2,064.92,048.8Goodwill 8,988.68,951.1Intangible assets, net 4,468.04,598.4Other assets 1,072.11,095.5Total Assets$ 22,183.9 $ 21,365.3Liabilities and Stockholders' Equity Current liabilities$ 1,695.0 $ 1,587.9Current portion of long-term debt 600.0863.0Other long-term liabilities 908.91,096.6Long-term debt 6,576.35,341.6Stockholders' equity 12,403.812,476.2Total Liabilities and Stockholders' Equity$ 22,183.9 $ 21,365.3 ZIMMER BIOMET HOLDINGS, CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024(in millions, unaudited) 2025 2024Cash flows provided by (used in) operating activities Net earnings$ 182.6 $ 172.8Depreciation and amortization 254.4238.6Share-based compensation 19.629.0Changes in operating assets and liabilities, net of acquired assets and liabilities Income taxes (15.6)(8.6)Receivables (18.8)(22.7)Inventories (3.0)(55.3)Accounts payable and accrued liabilities (36.4)(119.4)Other assets and liabilities (0.1)(6.4)Net cash provided by operating activities 382.8228.0Cash flows provided by (used in) investing activities Additions to instruments (59.7)(82.0)Additions to other property, plant and equipment (44.6)(55.1)Net investment hedge settlements 1.010.2Acquisition of intangible assets (2.4)(43.3)Other investing activities (0.3)(24.8)Net cash used in investing activities (106.0)(195.0)Cash flows provided by (used in) financing activities Net payments on revolving facilities -70.0Proceeds from senior notes 1,748.1-Redemption of senior notes (863.0)-Dividends paid to stockholders (47.8)(49.4)Proceeds from employee stock compensation plans 16.756.4Business combination contingent consideration payments (17.4)(1.5)Debt issuance costs (16.1)-Deferred business combination payments -(1.5)Repurchase of common stock (229.8)(113.6)Other financing activities (15.2)(10.5)Net cash provided by (used in) financing activities 575.4(50.1)Effect of exchange rates on cash and cash equivalents 7.0(5.7)Change in cash and cash equivalents 859.1(22.7)Cash and cash equivalents, beginning of year 525.5415.8Cash and cash equivalents, end of period$ 1,384.5 $ 393.0 ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF REPORTED NET SALES % CHANGE TO CONSTANT CURRENCY % CHANGE (unaudited)For the Three Months EndedMarch 31, 2025 vs. 2024ForeignConstantExchangeCurrency% ChangeImpact% Change Geographic ResultsUnited States1.3% -% 1.3% International0.7 (3.0) 3.7 Total1.1% (1.2)% 2.3% Product CategoriesKneesUnited States0.2% -% 0.2% International1.2 (3.0) 4.2 Total0.6 (1.3) 1.9 HipsUnited States3.7 - 3.7 International(2.0) (3.0) 1.0 Total0.9 (1.5) 2.4 S.E.T.3.9 (1.0) 4.9 Technology & Data, Bone Cement and Surgical(4.7) (1.2) (3.5) Total1.1% (1.2)... % 2.3% ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF PROJECTED FULL-YEAR 2025 REPORTED REVENUE CHANGE TO ORGANIC CONSTANT CURRENCY REVENUE CHANGE (unaudited)Projected Full-year 2025Reported revenue change 5.7 - 8.2 % Less: Foreign currency exchange impact 0.0 - 0.5Less: Paragon 28 2.7Organic constant currency revenue change 3.0 - 5.0 % ZIMMER BIOMET HOLDINGS, OF REPORTED TO ADJUSTED RESULTSFOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024(in millions, except per share amounts, unaudited)FOR THE THREE MONTHS ENDED MARCH 31, 2025Cost of products sold, excluding intangible asset amortization Intangible asset amortization Research and development Restructuring and other cost reduction initiatives Acquisition, integration, divestiture and related Interest expense, net Provision for income taxes Net Earnings of Zimmer Biomet Holdings, Inc. Diluted earnings per common shareAs Reported$ 549.8 $ 151.0 $ 110.6 $ 36.0 $ 10.6 $ (66.2) $ 46.5 $ 182.0 $ 0.91Inventory and manufacturing-related charges(1) (6.2)-----2.14.10.02Intangible asset amortization(2) -(151.0)----28.2122.80.61Restructuring and other cost reduction initiatives(3) ---(36.0)--7.228.80.14Acquisition, integration, divestiture and related(4) ----(10.6)-1.98.70.04European Union Medical Device Regulation(5) --(4.4)---0.93.50.02Other charges(6) -----4.82.72.10.01Other certain tax adjustments(7) ------(9.2)9.20.05As Adjusted$ 543.6 $ - $ 106.2 $ - $ - $ (61.4) $ 80.3 $ 361.2 $ 1.81 FOR THE THREE MONTHS ENDED MARCH 31, 2024Cost of products sold, excluding intangible asset amortization Intangible asset amortization Research and development Selling, general and administrative Restructuring and other cost reduction initiatives Acquisition, integration, divestiture and related Other income (expense), net Provision for income taxes Net Earnings of Zimmer Biomet Holdings, Inc. Diluted earnings per common shareAs Reported$ 512.3 $ 142.1 $ 107.9 $ 736.2 $ 124.4 $ 0.4 $ (0.1) $ 42.3 $ 172.4 $ 0.84Inventory and manufacturing-related charges(1) (1.1)------0.80.3-Intangible asset amortization(2) -(142.1)-----27.8114.30.55Restructuring and other cost reduction initiatives(3) ----(124.4)--27.896.60.47Acquisition, integration, divestiture and related(4) -----(0.4)-0.4--European Union Medical Device Regulation(5) --(5.7)----1.34.40.02Other charges(6) ---0.2--2.30.51.60.01Other certain tax adjustments(7) -------(10.0)10.00.05As Adjusted$ 511.2 $ - $ 102.2 $ 736.4 $ - $ - $ 2.1 $ 90.9 $ 399.7 $ 1.94(1) Inventory and manufacturing-related charges include excess and obsolete inventory charges on certain product lines we intend to discontinue, the acceleration of depreciation and fixed overhead costs expensed immediately related to a manufacturing plant shutdown, and other inventory and manufacturing-related charges or gains. (2) We exclude intangible asset amortization as well as deferred tax rate changes on our intangible assets from our non-GAAP financial measures because we internally assess our performance against our peers without this amortization. Due to various levels of acquisitions among our peers, intangible asset amortization can vary significantly from company to company. (3) In December 2019, 2021 and 2023, and in February 2025, we initiated global restructuring programs that included a reorganization of key businesses and an overall effort to reduce costs in order to accelerate decision-making, focus the organization on priorities to drive growth and, in the case of the December 2021 program, to prepare for the spinoff of ZimVie, Inc. ("ZimVie"). Restructuring and other cost reduction initiatives also include other cost reduction and optimization initiatives that have the goal of reducing costs across the organization. The costs include employee termination benefits; contract terminations for facilities and sales agents; and other charges, such as consulting fees, project management expenses, retention period salaries and benefits and relocation costs. (4) The acquisition, integration, divestiture and related gains and expenses we have excluded from our non-GAAP financial measures resulted from various acquisitions, post-separation costs we have incurred related to ZimVie and gains related to a transition services agreement for services we provide to ZimVie and a transition manufacturing and supply agreement for products we supply to ZimVie for a limited period. (5) The European Union Medical Device Regulation imposes significant additional premarket and postmarket requirements. The new regulations provided a transition period until May 2021 for previously-approved medical devices to meet the additional requirements. For certain devices, this transition period was extended until May 2024. A conditional extension of the transition period has been implemented until December 2027 and 2028 depending on the legacy medical device's risk class. We are excluding from our non-GAAP financial measures the incremental costs incurred to establish initial compliance with the regulations related to our previously-approved medical devices. The incremental costs primarily relate to temporary personnel and third-party professionals necessary to supplement our internal resources. (6) We have incurred other various expenses from specific events or projects that we consider highly variable or that have a significant impact to our operating results that we have excluded from our non-GAAP measures. These include gains and losses from changes in fair value on our equity investments, among other various costs. In addition, in February 2025 we issued senior notes in order to have the necessary cash-on-hand to acquire Paragon 28 once regulatory approval was received. We have excluded from our non-GAAP financial measures the interest on this debt related to the principal amount of the estimated purchase price and acquisition-related costs. (7) Other certain tax adjustments are related to certain significant and discrete tax adjustments including intercompany transactions between jurisdictions, ongoing impacts of tax only amortization resulting from certain restructuring transactions and impacts of significant tax reform including Swiss reform. ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 (in millions, unaudited)Three Months Ended March 31,2025 2024 Net cash provided by operating activities $ 382.8 $ 228.0 Additions to instruments(59.7)(82.0) Additions to other property, plant and equipment(44.6)(55.1) Free cash flow $ 278.5 $ 90.9 ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF GROSS PROFIT & MARGIN TO ADJUSTED GROSS PROFIT & MARGIN FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 (in millions, unaudited)Three Months Ended March 31,2025 2024 Net Sales $ 1,909.1 $ 1,889.2 Cost of products sold, excluding intangible asset amortization549.8512.3 Intangible asset amortization151.0142.1 Gross Profit $ 1,208.3 $ 1,234.8Inventory and manufacturing-related charges6.21.1 Intangible asset amortization151.0142.1 Adjusted gross profit $ 1,365.5 $ 1,378.0 Gross margin63.3%65.4% Inventory and manufacturing-related charges0.30.1 Intangible asset amortization7.97.5 Adjusted gross margin71.5%72.9% ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF OPERATING PROFIT & MARGIN TO ADJUSTED OPERATING PROFIT & MARGIN FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 (in millions, unaudited)Three Months Ended March 31,2025 2024 Operating profit $ 292.3 $ 265.9 Inventory and manufacturing-related charges6.21.1 Intangible asset amortization151.0142.1 Restructuring and other cost reduction initiatives36.0124.4 Acquisition, integration, divestiture and related10.60.4 European Union Medical Device Regulation4.45.7 Other charges-(0.2) Adjusted operating profit $ 500.5 $ 539.4 Operating profit margin15.3%14.1% Inventory and manufacturing-related charges0.30.1 Intangible asset amortization7.97.5 Restructuring and other cost reduction initiatives1.96.6 Acquisition, integration, divestiture and related0.6- European Union Medical Device Regulation0.20.3 Adjusted operating profit margin26.2%28.6% ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF EFFECTIVE TAX RATE TO ADJUSTED EFFECTIVE TAX RATE FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 (unaudited)Three Months Ended March 31,2025 2024 Effective tax rate20.3%19.7% Tax effect of adjustments made to earnings before taxes(1)1.93.4 Other certain tax adjustments (2)(4.0)(4.6) Adjusted effective tax rate18.2%18.5%(1) Includes inventory and manufacturing-related charges; intangible asset amortization; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; litigation; European Union Medical Device Regulation; and other charges (2) Other certain tax adjustments are related to certain significant and discrete tax adjustments including intercompany transactions between jurisdictions, ongoing impacts of tax only amortization resulting from certain restructuring transactions, and impacts of significant tax reform including Swiss reform. ZIMMER BIOMET HOLDINGS, OF DEBT TO NET DEBTAS OF MARCH 31, 2025 and DECEMBER 31, 2024(in millions, unaudited) March 31, 2025 December 31, 2024Debt, both current and long-term $ 7,176.3 $ 6,204.6Cash and cash equivalents(1,384.5)(525.5)Net debt $ 5,791.8 $ 5,679.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 Weiner(908) View original content to download multimedia: SOURCE Zimmer Biomet Holdings, Inc.
Yahoo
06-02-2025
- Business
- Yahoo
Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00 Company provides full-year 2025 financial guidance WARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024. The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over the prior year period, and an increase of 4.9% on a constant currency1 basis. Net sales for the full year were $7.679 billion, an increase of 3.8% over the prior year, and an increase of 4.8% on a constant currency1 basis. Net earnings for the fourth quarter were $239.4 million, or $462.4 million on an adjusted1 basis. For the full year, net earnings were $903.8 million, or $1.630 billion on an adjusted1 basis. Diluted earnings per share were $1.20 for the fourth quarter, and adjusted1 diluted earnings per share were $2.31. Full-year diluted earnings per share were $4.43, and adjusted1 diluted earnings per share were $8.00. "We are pleased with our fourth quarter results and strong performance to close 2024, delivering on our financial guidance and validating the solid work that the team is doing across the globe," said Ivan Tornos, Zimmer Biomet's President and Chief Executive Officer. "We have committed to diversifying our portfolio outside of core orthopedics and investing in attractive, higher-growth segments. Our recently announced agreement to acquire Paragon 28 marks a bold step towards executing on our diversification ambitions; once the transaction is closed, we expect our S.E.T. business to be larger than our Hip business, and to grow at a much faster pace." Recent Highlights Announced definitive agreement to acquire Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused exclusively on the foot and ankle orthopedic segment, demonstrating Zimmer Biomet's commitment to investing in higher growth end-markets with expansion into the ~$5 billion foot and ankle segment. Announced the U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the Oxford® Cementless Partial Knee. Following more than 20 years of clinical experience and over 300,000 procedures performed across Canada, Europe, Middle East, Africa, and Asia, the Oxford Cementless Partial Knee is the only FDA-approved cementless partial knee implant in the U.S. Announced FDA 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural humeral (upper shoulder bone) anatomy to optimize anatomical fit while maximizing preservation of healthy bone. Received CE Mark Certification for the Persona® Revision Knee System, building on Zimmer Biomet's commitment to personalized solutions, providing more surgeons with advanced tools for revision knee arthroplasty. Welcomed Arnold Schwarzenegger as Chief Movement Officer. In this strategic role, Mr. Schwarzenegger will collaborate with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster overall health and wellness and support the Company's Direct-to-Patient efforts. ________ 1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release. Geographic and Product Category Sales The following sales tables provide results by geography and product category for the three-month period and year ended December 31, 2024, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis. NET SALES - THREE MONTHS ENDED DECEMBER 31, 2024 (in millions, unaudited)Constant NetCurrency Sales% Change% ChangeGeographic Results United States $ 1,181.2 4.7 %4.7 % International842.0 3.7 5.2Total $ 2,023.2 4.3 %4.9 % Product Categories Knees United States $ 490.1 3.9 %3.9 % International349.1 6.8 8.0Total839.2 5.1 5.6Hips United States271.7 3.2 3.2International248.3 2.8 4.8Total520.0 3.0 4.0S.E.T. *489.4 8.0 8.4Technology & Data, Bone Cement and Surgical **174.6 (4.9) (4.3)Total $ 2,023.2 4.3 %4.9 %* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic** Historically referred to as "Other" NET SALES - YEAR ENDED DECEMBER 31, 2024 (in millions, unaudited) Constant Net Currency Sales % Change% ChangeGeographic ResultsUnited States $ 4,439.03.5 %3.5 % International3,239.64.3 6.6Total $ 7,678.63.8 %4.8 % Product CategoriesKneesUnited States $ 1,814.72.5 %2.5 % International1,358.87.2 9.1Total3,173.54.4 5.2HipsUnited States1,040.02.7 2.7International959.10.4 3.3Total1,999.11.6 3.0S.E.T. *1,865.76.5 7.1Technology & Data, Bone Cement and Surgical **640.30.7 1.9Total $ 7,678.63.8 %4.8 % * Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic ** Historically referred to as "Other" Amounts reported in millions are computed based on the actual amounts. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Percentages presented are calculated from the underlying unrounded amounts. Financial Guidance The Company is providing the following full-year 2025 financial guidance: Projected Year Ending December 31, 2025 2025 Reported Revenue Change 1.0% - 3.5% Foreign Currency Exchange Impact (2.0)% - (1.5)% 2025 Constant Currency Revenue Change 3.0% - 5.0% Adjusted Diluted EPS(1) $8.15 - $8.35(1) This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See "Forward-Looking Non-GAAP Financial Measures" below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure. Conference Call The Company will conduct its fourth quarter and full-year 2024 investor conference call today, February 6, 2025, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at It will be archived for replay following the conference call. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit or follow on LinkedIn at or X / Twitter at Website Information We routinely post important information for investors on our website, in the "Investor Relations" section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website or any other website referenced herein is not incorporated by reference into, and is not a part of, this document. Note on Non-GAAP Financial Measures This press release and our commentary in our investor conference call today include non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP. Net sales change information for the three-month period and the year ended December 31, 2024 is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases. Net earnings and diluted earnings per share for the three-month periods and the years ended December 31, 2024 and 2023 are presented on a GAAP (reported) basis and on an adjusted basis. These adjusted financial measures exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in the press release. Free cash flow is an additional non-GAAP measure that is presented in this press release. Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash provided by operating activities. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release. This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company presents in other contexts. These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation. Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures. In addition, constant currency sales changes, adjusted operating profit, adjusted diluted earnings per share and free cash flow are used as performance metrics in our incentive compensation programs. Forward-Looking Non-GAAP Financial Measures This press release and our commentary in our investor conference call today also include certain forward-looking non-GAAP financial measures for the year ending December 31, 2025. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, we exclude the impact of certain charges related to initial compliance with the European Union Medical Device Regulation; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; and certain legal and tax matters. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding financial guidance, statements regarding macro pressures, including the impact of such pressures on our business, and any statements about our forecasts, expectations, plans, intentions, strategies or prospects. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: competition; pricing pressures; dependence on new product development, technological advances and innovation; changes in customer demand for our products and services caused by demographic changes, obsolescence, development of different therapies or other factors; our ability to attract, retain, develop and maintain adequate succession plans for the highly skilled employees, senior management, independent agents and distributors we need to support our business; shifts in the product category or regional sales mix of our products and services; the risks and uncertainties related to our ability to successfully execute our restructuring plans; control of costs and expenses; risks related to the satisfaction of the conditions to closing the proposed transaction with Paragon 28 (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as whether the stockholders of Paragon 28 will approve the proposed transaction and the possibility that the proposed transaction does not close; risks related to the ability to realize the anticipated benefits of the proposed transaction with Paragon 28, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses of will not be integrated successfully; disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including with customers, vendors, service providers, independent sales representatives, agents or agencies; the effects of business disruptions affecting us, our suppliers, customers or payors, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; unplanned delays, disruptions and expenses attributable to our enterprise resource planning and other system updates; the ability to form and implement alliances; dependence on a limited number of suppliers for key raw materials and other inputs and for outsourced activities; the risk of disruptions in the supply of materials and components used in manufacturing or sterilizing our products; breaches or failures of our (or of our business partners' or other third parties') information technology systems or products, including by cyberattack, unauthorized access or theft; the outcome of government investigations; the impact of healthcare reform and cost containment measures, including efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, through reductions in reimbursement levels, repayment demands and otherwise; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; changes in tax obligations arising from examinations by tax authorities and from changes in tax laws in jurisdictions where we do business, including as a result of the "base erosion and profit shifting" project undertaken by the Organisation for Economic Co-operation and Development and otherwise; challenges to the tax-free nature of the ZimVie Inc. spinoff transaction and the subsequent liquidation of our retained interest in ZimVie Inc.; the risk of additional tax liability due to the recategorization of our independent agents and distributors to employees; changes in tariffs relating to imports to the U.S. and other countries; the risk that material impairment of the carrying value of our intangible assets, including goodwill, could negatively affect our operating results; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; changes in general industry and market conditions, including domestic and international growth, inflation and currency exchange rates; the domestic and international business impact of political, social and economic instability, tariffs, trade restrictions and embargoes, sanctions, wars, disputes and other conflicts, including on our ability to operate in, export from or collect accounts receivable in affected countries; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration ("FDA") and other government regulators relating to medical products, healthcare fraud and abuse laws and data privacy and cybersecurity laws; the success of our quality and operational excellence initiatives; the ability to remediate matters identified in inspectional observations issued by the FDA and other regulators, while continuing to satisfy the demand for our products; product liability, intellectual property and commercial litigation losses; and the ability to obtain and maintain adequate intellectual property protection. A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and our subsequent filings with the Securities and Exchange Commission (SEC). Copies of these filings are available online at or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release. Note: Amounts reported in millions within this press release are computed based on the actual amounts. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts. ZIMMER BIOMET HOLDINGS, STATEMENTS OF EARNINGSFOR THE THREE MONTHS ENDED DECEMBER 31, 2024 and 2023(in millions, except per share amounts, unaudited) 2024 2023Net Sales $ 2,023.2 $ 1,940.1Cost of products sold, excluding intangible asset amortization586.7538.8Intangible asset amortization157.6144.9Research and development108.4113.3Selling, general and administrative746.9722.3Restructuring and other cost reduction initiatives20.961.3Acquisition, integration, divestiture and related13.75.3Operating expenses1,634.21,585.9Operating Profit389.0354.2Other expense, net(38.1)(19.5)Interest expense, net(61.9)(50.3)Earnings before income taxes289.0284.4Provision (benefit) for income taxes49.0(135.2)Net Earnings240.0419.6Less: Net earnings attributable to noncontrolling interest0.60.5Net Earnings of Zimmer Biomet Holdings, Inc. $ 239.4 $ 419.2Earnings Per Common ShareBasic $ 1.20 $ 2.02Diluted $ 1.20 $ 2.01Weighted Average Common Shares OutstandingBasic199.1207.9Diluted199.9208.6 ZIMMER BIOMET HOLDINGS, STATEMENTS OF EARNINGSFOR THE YEARS ENDED DECEMBER 31, 2024 and 2023(in millions, except per share amounts, unaudited) 2024 2023Net Sales $ 7,678.6 $ 7,394.2Cost of products sold, excluding intangible asset amortization2,191.22,083.8Intangible asset amortization591.9561.5Research and development437.4458.7Selling, general and administrative2,929.82,838.9Restructuring and other cost reduction initiatives219.0151.9Acquisition, integration, divestiture and related23.621.7Operating expenses6,392.96,116.5Operating Profit1,285.71,277.7Other expense, net(31.1)(9.3)Interest expense, net(218.0)(201.2)Earnings before income taxes1,036.61,067.3Provision for income taxes131.442.2Net Earnings905.21,025.1Less: Net earnings attributable to noncontrolling interest1.51.1Net Earnings of Zimmer Biomet Holdings, Inc. $ 903.8 $ 1,024.0Earnings Per Common ShareBasic $ 4.45 $ 4.91Diluted $ 4.43 $ 4.88Weighted Average Common Shares OutstandingBasic203.1208.7Diluted203.9209.7 ZIMMER BIOMET HOLDINGS, CONSOLIDATED BALANCE SHEETS(in millions, unaudited)December 31, December 31,2024 2023Assets Cash and cash equivalents$ 525.5 $ 415.8Receivables, net 1,480.71,442.4Inventories 2,235.32,385.2Other current assets 430.1366.1Total current assets 4,671.54,609.5Property, plant and equipment, net 2,048.82,060.4Goodwill 8,951.18,818.5Intangible assets, net 4,598.44,856.4Other assets 1,095.51,152.1Total Assets$ 21,365.3 $ 21,496.9Liabilities and Stockholders' Equity Current liabilities$ 1,587.9 $ 1,957.5Current portion of long-term debt 863.0900.0Other long-term liabilities 1,096.61,283.4Long-term debt 5,341.64,867.9Stockholders' equity 12,476.212,488.1Total Liabilities and Stockholders' Equity$ 21,365.3 $ 21,496.9 ZIMMER BIOMET HOLDINGS, STATEMENTS OF CASH FLOWSFOR THE YEARS ENDED DECEMBER 31, 2024 and 2023(in millions, unaudited) 2024... 2023Cash flows provided by (used in) operating activities Net earnings$ 905.2 $ 1,025.1Depreciation and amortization 996.3951.7Share-based compensation 101.099.8Gain on investment in ZimVie Inc. -(2.5)Deferred income tax benefit (47.7)(96.3)Changes in operating assets and liabilities, net of acquired assets and liabilities Income taxes (158.6)(73.8)Receivables (89.7)(51.9)Inventories 49.9(240.4)Accounts payable and accrued liabilities (322.0)(55.3)Other assets and liabilities 65.025.2Net cash provided by operating activities 1,499.41,581.6Cash flows provided by (used in) investing activities Additions to instruments (240.3)(311.7)Additions to other property, plant and equipment (203.8)(291.1)Net investment hedge settlements 22.133.4Acquisition of intangible assets (153.0)(103.4)Business combination investments, net of acquired cash (276.3)(134.9)Other investing activities (36.9)28.8Net cash used in investing activities (888.1)(778.9)Cash flows provided by (used in) financing activities Net payments on revolving facilities (50.0)(325.0)Proceeds from senior notes 1,436.3499.8Redemption of senior notes (850.0)(86.3)Payment on term loan -(33.9)Dividends paid to stockholders (196.0)(200.9)Proceeds from employee stock compensation plans 82.1101.1Business combination contingent consideration payments (3.5)(10.3)Debt issuance costs (13.0)(5.8)Deferred business combination payments (8.8)(4.0)Repurchase of common stock (868.0)(692.2)Other financing activities (13.6)(6.1)Net cash used in financing activities (484.5)(763.5)Effect of exchange rates on cash and cash equivalents (17.1)0.9Change in cash and cash equivalents 109.740.1Cash and cash equivalents, beginning of year 415.8375.7Cash and cash equivalents, end of period$ 525.5 $ 415.8 ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF REPORTED NET SALES % CHANGE TO CONSTANT CURRENCY % CHANGE (unaudited) For the Three Months Ended December 31, 2024 vs. 2023 ForeignConstant ExchangeCurrency % ChangeImpact% ChangeGeographic Results United States4.7 %- %4.7 % International3.7 (1.5) 5.2Total4.3 %(0.6) %4.9 % Product Categories Knees United States3.9 %- %3.9 % International6.8 (1.2) 8.0Total5.1 (0.5) 5.6Hips United States3.2 - 3.2International2.8 (2.0) 4.8Total3.0 (1.0) 4.0S.E.T.8.0 (0.4) 8.4Technology & Data, Bone Cement andSurgical(4.9) (0.6) (4.3)Total4.3 %(0.6) %4.9 % ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF REPORTED NET SALES % CHANGE TO CONSTANT CURRENCY % CHANGE (unaudited) For the Year Ended December 31, 2024 vs. 2023Foreign ConstantExchange Currency % Change Impact % ChangeGeographic Results United States3.5 % - % 3.5 % International4.3(2.3)6.6Total3.8 % (1.0) % 4.8 % Product Categories Knees United States2.5 % - % 2.5 % International7.2(1.9)9.1Total4.4(0.8)5.2Hips United States2.7-2.7International0.4(2.9)3.3Total1.6(1.4)3.0S.E.T.6.5(0.6)7.1Technology & Data, Bone Cement andSurgical0.7(1.2)1.9Total3.8 % (1.0) % 4.8 % ZIMMER BIOMET HOLDINGS, OF REPORTED TO ADJUSTED RESULTSFOR THE THREE MONTHS ENDED DECEMBER 31, 2024 and 2023(in millions, except per share amounts, unaudited) FOR THE THREE MONTHS ENDED DECEMBER 31, 2024Cost of products sold, excludingintangibleassetamortization Intangible assetamortization Researchand development Selling, general and administrative Restructuringand other cost reductioninitiatives Acquisition, integration, divestiture andrelated Other expense,net Provision (benefit)for income taxes Net Earningsof Zimmer Biomet Holdings, Inc. Diluted earningspercommon shareAs Reported$ 586.7 $ 157.6 $ 108.4 $ 746.9 $ 20.9 $ 13.7 $ (38.1) $ 49.0 $ 239.4 $ 1.20Inventory and manufacturing-related charges(1) (6.0)------2.23.80.02Intangible asset amortization(2) -(157.6)-----30.8126.80.63Restructuring and other cost reduction initiatives(3) ----(20.9)--0.820.10.10Acquisition, integration, divestiture and related(4) -----(13.7)-1.012.70.06Litigation(5) ---(27.4)---4.023.40.12European Union Medical Device Regulation(6) --(7.6)----1.75.90.03Other charges(7) ---(0.9)--37.71.137.50.19Other certain tax adjustments(8) -------7.3(7.3)(0.04)As Adjusted$ 580.7 $ - $ 100.8 $ 718.6 $ - $ - $ (0.4) $ 97.9 $ 462.4 $ 2.31 FOR THE THREE MONTHS ENDED DECEMBER 31, 2023Cost of products sold, excludingintangible asset amortization Intangibleasset amortization Research anddevelopment Selling,general and administrative Restructuringand other cost reductioninitiatives Acquisition, integration, divestiture and related Other expense, net Provision (benefit) forincometaxes NetEarningsof Zimmer Biomet Holdings, Inc. Diluted earningsper commonshareAs Reported$ 538.8 $ 144.9 $ 113.3 $ 722.3 $ 61.3 $ 5.3 $ (19.5) $ (135.2) $ 419.2 $ 2.01Inventory and manufacturing-related charges(1) (4.9)------(0.3)5.20.02Intangible asset amortization(2) -(144.9)-----29.0115.90.56Restructuring and other cost reduction initiatives(3) ----(61.3)--19.342.00.20Acquisition, integration, divestiture and related(4) -----(5.3)-0.35.00.02Litigation(5) ---(13.9)---4.79.20.04European Union MedicalDevice Regulation(6) --(13.5)----3.210.30.05Other charges(7) ---9.6--26.4(2.4)19.20.09Other certain tax adjustments(8) -------167.8(167.8)(0.80)As Adjusted$ 533.9 $ - $ 99.7 $ 717.9 $ - $ - $ 6.9 $ 86.4 $ 458.1 $ 2.20 ZIMMER BIOMET HOLDINGS, OF REPORTED TO ADJUSTED RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024 and 2023(in millions, except per share amounts, unaudited) FOR THE YEAR ENDED DECEMBER 31, 2024Cost of productssold, excludingintangibleassetamortization Intangible asset amortization Research anddevelopment Selling,general and administrative Restructuring and othercost reductioninitiatives Acquisition,integration, divestiture and related Other expense, net Provisionfor incometaxes Net EarningsofZimmer Biomet Holdings,Inc. Diluted earningsper commonshareAs Reported$ 2,191.2 $ 591.9 $ 437.4 $ 2,929.8 $ 219.0 $ 23.6 $ (31.1) $ 131.4 $ 903.8 $ 4.43Inventory and manufacturing-related charges(1) (19.2)------7.212.00.06Intangible asset amortization(2) -(591.9)-----121.2470.72.31Restructuring and other costreduction initiatives(3) ----(219.0)--35.3183.70.90Acquisition, integration, divestiture and related(4) -----(23.6)-2.421.20.10Litigation(5) ---(27.4)---4.722.70.12European Union Medical DeviceRegulation(6) --(28.6)----6.622.00.11Other charges(7) ------42.42.440.00.20Other certain tax adjustments(8) -------46.0(46.0)(0.23)As Adjusted$ 2,172.0 $ - $ 408.8 $ 2,902.4 $ - $ - $ 11.3 $ 357.2 $ 1,630.2 $ 8.00 FOR THE YEAR ENDED DECEMBER 31, 2023Cost ofproducts sold, excluding intangible asset amortization Intangible asset amortization Research and development Selling,general andadministrative Restructuring and othercost reductioninitiatives Acquisition,integration, divestitureand related Other expense, net Provisionfor incometaxes Net Earningsof Zimmer Biomet Holdings, Inc. Diluted earnings per commonshareAs Reported$ 2,083.8 $ 561.5 $ 458.7 $ 2,838.9 $ 151.9 $ 21.7 $ (9.3) $ 42.2 $ 1,024.0 $ 4.88Inventory and manufacturing-related charges(1) (18.3)------7.510.80.05Intangible asset amortization(2) -(561.5)-----113.9447.62.13Restructuring and other cost reductioninitiatives(3) ----(151.9)--39.8112.10.53Acquisition, integration, divestiture andrelated(4) -----(21.7)-0.721.00.10Litigation(5) ---(10.1)---3.96.20.03European Union Medical Device Regulation(6) --(56.1)----13.143.00.21Other charges(7) ---10.6--16.6(9.5)15.50.07Other certain tax adjustments(8) -------96.0(96.0)(0.46)As Adjusted$ 2,065.4 $ - $ 402.6 $ 2,839.4 $ - $ - $ 7.4 $ 307.6 $ 1,584.2 $ 7.55(1) Inventory and manufacturing-related charges include excess and obsolete inventory charges on certain product lines we intend to discontinue, the acceleration of depreciation and fixed overhead costs expensed immediately related to a manufacturing plant shutdown, and other inventory and manufacturing-related charges or gains. (2) We exclude intangible asset amortization as well as deferred tax rate changes on our intangible assets from our non-GAAP financial measures because we internally assess our performance against our peers without this amortization. Due to various levels of acquisitions among our peers, intangible asset amortization can vary significantly from company to company. (3) In December 2019, 2021, and 2023 we initiated global restructuring programs that included a reorganization of key businesses and an overall effort to reduce costs in order to accelerate decision-making, focus the organization on priorities to drive growth and, in the case of the December 2021 program, to prepare for the spinoff of ZimVie, Inc. ("ZimVie"). Restructuring and other cost reduction initiatives also include other cost reduction and optimization initiatives that have the goal of reducing costs across the organization. The costs include employee termination benefits; contract terminations for facilities and sales agents; and other charges, such as consulting fees, project management expenses, retention period salaries and benefits and relocation costs. (4) The acquisition, integration, divestiture and related gains and expenses we have excluded from our non-GAAP financial measures resulted from various acquisitions, post-separation costs we have incurred related to ZimVie and gains related to a transition services agreement for services we provide to ZimVie and a transition manufacturing and supply agreement for products we supply to ZimVie for a limited period. (5) We are involved in patent litigation, product liability litigation, commercial litigation and other various litigation matters. We review litigation matters from both a qualitative and quantitative perspective to determine if excluding the losses or gains will provide our investors with useful incremental information. Litigation matters can vary in their characteristics, frequency and significance to our operating results. The litigation charges and gains excluded from our non-GAAP financial measures in the periods presented relate to patent litigation, product liability litigation and commercial litigation. Once the litigation matter has been excluded from our non-GAAP financial measures in a particular period, any additional expenses or gains from changes in estimates are also excluded, even if they are not significant, to ensure consistency in our non-GAAP financial measures from period-to-period. (6) The European Union Medical Device Regulation imposes significant additional premarket and postmarket requirements. The new regulations provided a transition period until May 2021 for previously-approved medical devices to meet the additional requirements. For certain devices, this transition period was extended until May 2024. A conditional extension of the transition period has been implemented until December 2027 and 2028 depending on the legacy medical device's risk class. We are excluding from our non-GAAP financial measures the incremental costs incurred to establish initial compliance with the regulations related to our previously-approved medical devices. The incremental costs primarily relate to temporary personnel and third-party professionals necessary to supplement our internal resources. (7) We have incurred other various expenses from specific events or projects that we consider highly variable or that have a significant impact to our operating results that we have excluded from our non-GAAP measures. These include gains and losses from changes in fair value on our equity investments, among other various costs. (8) Other certain tax adjustments are related to certain significant and discrete tax adjustments including intercompany transactions between jurisdictions, ongoing impacts of tax only amortization resulting from certain restructuring transactions, impacts of significant tax reform including Swiss reform and certain favorable tax settlements. ZIMMER BIOMET HOLDINGS, OF NET CASH PROVIDED BY OPERATINGACTIVITIES TO FREE CASH FLOWFOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2024 and 2023(in millions, unaudited) Three Months Ended December 31,Years Ended December 31, 2024 202320242023Net cash provided by operating activities $ 506.2 $ 588.4$ 1,499.4$ 1,581.6Additions to instruments(51.9)(79.0) (240.3) (311.7)Additions to other property, plant and equipment(51.5)(62.9) (203.8) (291.1)Free cash flow $ 402.8 $ 446.5$ 1,055.3$ 978.8 ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF GROSS PROFIT & MARGIN TO ADJUSTED GROSS PROFIT & MARGIN FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2024 and 2023 (in millions, unaudited) Three Months Ended December 31, Years Ended December 31,2024 2023 2024 2023 Net Sales $ 2,023.2 $ 1,940.1 $ 7,678.6 $ 7,394.2 Cost of products sold, excludingintangible asset amortization586.7538.82,191.22,083.8 Intangible asset amortization157.6144.9591.9561.5 Gross Profit $ 1,278.9 $ 1,256.4 $ 4,895.5 $ 4,748.9Inventory and manufacturing-relatedcharges6.04.919.218.3 Intangible asset amortization157.6144.9591.9561.5 Adjusted gross profit $ 1,442.5 $ 1,406.2 $ 5,506.7 $ 5,328.8 Gross margin63.2%64.8%63.8%64.2% Inventory and manufacturing-relatedcharges0.30.30.30.3 Intangible asset amortization7.87.57.77.6 Adjusted gross margin71.3%72.5%71.7%72.1% ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF OPERATING PROFIT & MARGINTO ADJUSTED OPERATING PROFIT & MARGIN FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2024 and 2023 (in millions, unaudited) Three Months Ended December 31, Years Ended December 31,2024 2023 2024 2023 Operating profit $ 389.0 $ 354.2 $ 1,285.7 $ 1,277.7 Inventory and manufacturing-related charges6.04.919.218.3 Intangible asset amortization157.6144.9591.9561.5 Restructuring and other costreduction initiatives20.961.3219.0151.9 Acquisition, integration, divestiture and related13.75.323.621.7 Litigation27.413.927.410.1 European Union Medical DeviceRegulation7.613.528.656.1 Other charges0.9(9.6)-(10.6) Adjusted operating profit $ 623.2 $ 588.5 $ 2,195.4 $ 2,086.9 Operating profit margin19.2%18.3%16.7%17.3% Inventory and manufacturing-related charges0.30.30.30.2 Intangible asset amortization7.87.57.77.6 Restructuring and other costreduction initiatives1.03.22.92.1 Acquisition, integration, divestiture and related0.70.30.30.3 Litigation1.40.70.40.1 European Union Medical DeviceRegulation0.40.70.40.8 Other charges-(0.5)-(0.1) Adjusted operating profit margin30.8%30.3%28.6%28.2% ZIMMER BIOMET HOLDINGS, INC. RECONCILIATION OF EFFECTIVE TAX RATE TO ADJUSTED EFFECTIVE TAX RATE FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2024 and 2023 (unaudited)Three Months Ended December 31,Years Ended December 31,2024 20232024 2023 Effective tax rate16.9%(47.6)% 12.7%4.0% Tax effect of adjustments made toearnings before taxes(1)(1.9)4.5 0.83.3 Other certain tax adjustments (2)2.558.9 4.59.0 Adjusted effective tax rate17.5%15.8% 18.0%16.3%(1) Includes inventory and manufacturing-related charges; intangible asset amortization; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; litigation; European Union Medical Device Regulation; and other charges (2) Other certain tax adjustments are related to certain significant and discrete tax adjustments including intercompany transactions between jurisdictions, ongoing impacts of tax only amortization resulting from certain restructuring transactions, impacts of significant tax reform including Swiss reform, and certain favorable tax settlements. ZIMMER BIOMET HOLDINGS, OF DEBT TO NET DEBTAS OF DECEMBER 31, 2024 and 2023(in millions, unaudited) December 31, 2024 December 31, 2023Debt, both current and long-term $ 6,204.6 $ 5,767.9Cash and cash equivalents(525.5)(415.8)Net debt $ 5,679.1 $ 5,352.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 Weiner(908) View original content to download multimedia: SOURCE Zimmer Biomet Holdings, Inc. Sign in to access your portfolio
